SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $790,701 | -19.7% | 54,456 | +15.7% | 0.00% | -33.3% |
| Q2 2023 | $984,882 | -11.0% | 47,056 | -10.2% | 0.00% | 0.0% |
| Q1 2023 | $1,106,456 | -18.7% | 52,389 | -2.0% | 0.00% | -25.0% |
| Q4 2022 | $1,360,226 | +22.5% | 53,447 | +15.7% | 0.00% | 0.0% |
| Q3 2022 | $1,110,000 | +32.5% | 46,213 | +6.1% | 0.00% | +100.0% |
| Q2 2022 | $838,000 | -17.2% | 43,574 | -25.1% | 0.00% | 0.0% |
| Q1 2022 | $1,012,000 | -20.6% | 58,200 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,274,000 | -10.7% | 58,200 | -22.0% | 0.00% | -33.3% |
| Q3 2021 | $1,426,000 | +9.3% | 74,600 | -1.8% | 0.00% | 0.0% |
| Q2 2021 | $1,305,000 | +9.1% | 76,000 | +42.1% | 0.00% | 0.0% |
| Q1 2021 | $1,196,000 | +5.8% | 53,500 | +5.3% | 0.00% | 0.0% |
| Q4 2020 | $1,130,000 | +32.5% | 50,800 | -12.1% | 0.00% | +50.0% |
| Q3 2020 | $853,000 | +43.1% | 57,800 | +43.8% | 0.00% | 0.0% |
| Q2 2020 | $596,000 | +47.9% | 40,200 | +9.5% | 0.00% | +100.0% |
| Q1 2020 | $403,000 | +52.7% | 36,700 | +21.9% | 0.00% | 0.0% |
| Q4 2019 | $264,000 | +17.3% | 30,100 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $225,000 | +25.7% | 30,100 | +56.8% | 0.00% | – |
| Q2 2019 | $179,000 | +80.8% | 19,200 | +2.1% | 0.00% | – |
| Q1 2019 | $99,000 | +54.7% | 18,800 | +30.6% | 0.00% | – |
| Q4 2018 | $64,000 | – | 14,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |